Akeso, Inc. (AKESO, 9926.HK) is listed on HKEX. The latest available quote update was captured at 2026-03-26 10:40:17.0.
Quote Snapshot
- Last Price: 123.700 HKD
- Day Change: +1.900 (+1.56%)
- Open: 125.500 HKD
- High: 129.700 HKD
- Low: 122.700 HKD
- Previous Close: 121.800 HKD
- Volume: 13.28 M
- Market Cap: 113.94 B
- P/E Ratio: N/A
- Dividend Yield: N/A
- Board Lot: 1,000
- ISIN: KYG0146B1032
- Industry: Healthcare - Pharmaceuticals & Biotechnology
Company Overview
Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company’s products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.
Risk & Return Metrics
Based on 490 trading days of close price data (daily returns, annualized using 252 trading days).
| Metric | Daily | Annualized |
|---|---|---|
| Expected Return | 0.2890% | 106.96% |
| Risk (Std Dev) | 4.3732% | 69.42% |
| Metric | Value |
|---|---|
| First Price (HKD) | 46.950 |
| Last Price (HKD) | 121.800 |
| Total Return | 159.42% |